Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase MONROVIA, Calif., Sept. 25, 2023 /PRNewswire/ — AcuraStem, a patient-based biotechnology company pioneering how treatments…
